About farahnaz forozan

Over the past two decades, Dr. Forozan has built a spectrum of expertise and experience pertaining to pharmaceutical, biotech, diagnostics, clinical trials, and CRO/Central lab industries with specialized expertise in oncology, immuno-oncology, neurology, and microbiomes through an array of roles at Cedars-Sinai Medical Center, Genzyme, LabCorp/Covance, and Bristol Myers Squibb.

Farahnaz advises clients via Forozan OncoGen Consulting where she provides technical, regulatory, clinical operation, and diagnostics expertise to the life science ecosystem.  She also provides strategy, diligence, market analysis, and scientific intelligence on a array of projects including: complex & comprehensive R&D; early-stage, pre-clinical, and clinical stage assets and trials; evaluation of new platforms and technologies; drug discovery, drug development, biomarker identification and development; and assay development.  Dr. Forozan also has completed build outs of translational, diagnostic, and prognostic labs, developed regulatory strategy (including diagnostics, companion as well as in vitro diagnostics); and delivered on preclinical & clinical pipeline from discovery through launch.

Her clients include venture capital firms, angel investors, investment firms, consulting firms, hospitals, biotech and pharma companies, research academic centers, and CROs.

She has collaborated closely with companies (including Illumina, DAKO, Agilent, Ventana, Leica, Qiagen, nanoString, and Abbott) implementing global, multisite, companion and in vitro diagnostics/device studies in the U.S as well as China, the EU, and Australia, with direct contributions to regulatory authorities including FDA, cFDA, EMA, and TGA.Farahnaz has a proven track having contributed to the development, approval, and post-marketing support of more than 15 marketed products and over 30 global programs in various stages of clinical development.

Dr. Forozan was born in Iran, moved to Scandinavia after finishing high school and eventually to US where she completed her higher education. She received her Ph.D. in 2000 with a degree in Genetics through a joint program between The George Washington University and the National Institutes of Health. She received her B.S. in Biology/Genetics Engineering from California State University, Los Angeles. She is a Clinical Ph.D. and licensed (Clinical Genetic Molecular Biology Scientist) in State of California.